XML 29 R18.htm IDEA: XBRL DOCUMENT
v3.24.1

Insider Trading Arrangements shares in Thousands | 3 Months Ended | 6 Months Ended
--- | --- | ---
Feb. 29, 2024 shares | Feb. 29, 2024 shares
Trading Arrangements, by Individual |  |
Material Terms of Trading Arrangement |  | The adoption or termination of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers and directors for the quarter ended February 29, 2024, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (“Rule 10b5-1 Plan”), were as follows:
Name |  | Title |  | Action |  | Date Adopted |  | Expiration Date |  | Aggregate # of Securities to be Purchased/Sold
Dr. Lisa LaVange (1) |  | Director |  | Termination |  | 01/11/2023 |  | 01/20/2024 |  | 5,340 |
John DiBella (2) |  | Business Unit President |  | Termination |  | 01/31/2023 |  | 02/27/2024 |  | 41,505 |
Dr. Lisa LaVange (1) |  | Director |  | Adoption |  | 02/06/2024 |  | 02/08/2025 |  | 4,600 |
Dr. Daniel Wiener (3) |  | Director |  | Termination |  | 01/17/2023 |  | 02/06/2024 |  | 9,874 |
Dr. Daniel Wiener (3) |  | Director |  | Adoption |  | 02/06/2024 |  | 02/08/2025 |  | 12,000 |
(1) On January 20, 2024, the pre-arranged stock trading plan pursuant to Rule 10b5-1, adopted by Dr. Lisa LaVange on January 11, 2023, automatically terminated pursuant to its terms. The expired plan provided for (i) the potential exercise of vested stock options and the associated sale of up to 4,000 shares of Company common stock underlying such options, and (ii) the potential sale of up to an additional 1,340 shares of Company common stock until January 20, 2024. On February 6, 2024, Dr. LaVange entered into a new pre-arranged stock trading plan pursuant to Rule 10b5-1, which provides for (i) the potential exercise of vested stock options and the associated sale of up to 1,000 shares of Company common stock underlying such options, and (ii) the potential sale of up to an additional 3,600 shares of Company common stock. The new plan expires on February 8, 2025, or upon the earlier completion of all authorized transactions under the new plan. (2) On February 27, 2024, the pre-arranged stock trading plan pursuant to Rule 10b5-1, adopted by John DiBella on January 31, 2023, automatically terminated pursuant to its terms. The expired plan provided for the potential sale of up to 41,505 shares of Company common stock until February 27, 2024. (3) On February 6, 2024, Dr. Daniel Weiner materially amended that pre-arranged stock trading plan pursuant to Rule 10b5-1 adopted by Dr. Weiner on January 17, 2023, resulting in an effective termination of such plan and adoption of a new pre-arranged stock trading plan pursuant to Rule 10b5-1. Prior to the amendment (and effective termination), the plan provided for (i) the potential exercise of vested stock options and the associated sale of up to 6,000 shares of Company common stock underlying such options, and (ii) the potential sale of up to an additional 3,874 shares of Company common stock until January 27, 2025. As amended, the plan provides for (i) the potential exercise of vested stock options and the associated sale of up to 6,000 shares of Company common stock underlying such options, and (ii) the potential sale of up to an additional 6,000 shares of Company common stock. The plan, as amended, expires on February 8, 2025, or upon the earlier completion of all authorized transactions under the plan The Rule 10b5-1 trading arrangements described above were adopted and precleared in accordance with the Company’s Insider Trading Policy and actual sale transactions made pursuant to such trading arrangements will be disclosed publicly in future Section 16 filings with the SEC. Other than those disclosed above, none of our directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” in each case as defined in Item 408 of Regulation S-K.
Non-Rule 10b5-1 Arrangement Adopted | false |
Non-Rule 10b5-1 Arrangement Terminated | false |
Dr. Lisa LaVange January 2023 Plan [Member] |  |
Trading Arrangements, by Individual |  |
Name | Dr. Lisa LaVange |
Title | Director |
Adoption Date | 01/11/2023 |
Rule 10b5-1 Arrangement Terminated | true |
Termination Date | 01/20/2024 |
Arrangement Duration | 374 days |
Aggregate Available | 5,340 | 5,340
John DiBella January 2023 Plan [Member] |  |
Trading Arrangements, by Individual |  |
Name | John DiBella |
Title | Business Unit President |
Adoption Date | 01/31/2023 |
Rule 10b5-1 Arrangement Terminated | true |
Termination Date | 02/27/2024 |
Arrangement Duration | 392 days |
Aggregate Available | 41,505 | 41,505
Dr. Lisa LaVange February 2024 Plan [Member] |  |
Trading Arrangements, by Individual |  |
Name | Dr. Lisa LaVange |
Title | Director |
Rule 10b5-1 Arrangement Adopted | true |
Adoption Date | 02/06/2024 |
Arrangement Duration | 368 days |
Aggregate Available | 4,600 | 4,600
Dr. Daniel Wiener January 2023 Plan [Member] |  |
Trading Arrangements, by Individual |  |
Name | Dr. Daniel Wiener |
Title | Director |
Adoption Date | 01/17/2023 |
Rule 10b5-1 Arrangement Terminated | true |
Termination Date | 02/06/2024 |
Arrangement Duration | 385 days |
Aggregate Available | 9,874 | 9,874
Dr. Daniel Wiener February 2024 Plan [Member] |  |
Trading Arrangements, by Individual |  |
Name | Dr. Daniel Wiener |
Title | Director |
Rule 10b5-1 Arrangement Adopted | true |
Adoption Date | 02/06/2024 |
Arrangement Duration | 368 days |
Aggregate Available | 12,000 | 12,000

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details
Name: | ecd_MtrlTermsOfTrdArrTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details
Name: | ecd_NonRule10b51ArrAdoptedFlag
Namespace Prefix: | ecd_
Data Type: | xbrli:booleanItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details
Name: | ecd_NonRule10b51ArrTrmntdFlag
Namespace Prefix: | ecd_
Data Type: | xbrli:booleanItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details
Name: | ecd_Rule10b51ArrAdoptedFlag
Namespace Prefix: | ecd_
Data Type: | xbrli:booleanItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details
Name: | ecd_Rule10b51ArrTrmntdFlag
Namespace Prefix: | ecd_
Data Type: | xbrli:booleanItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details
Name: | ecd_TradingArrByIndTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph B + Details
Name: | ecd_TrdArrAdoptionDate
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph C + Details
Name: | ecd_TrdArrDuration
Namespace Prefix: | ecd_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details
Name: | ecd_TrdArrIndName
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details
Name: | ecd_TrdArrIndTitle
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph D + Details
Name: | ecd_TrdArrSecuritiesAggAvailAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph B + Details
Name: | ecd_TrdArrTerminationDate
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ecd_IndividualAxis=simu_Dr.LisaLaVangeJanuary2023PlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=simu_JohnDiBellaJanuary2023PlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=simu_Dr.LisaLaVangeFebruary2024PlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=simu_Dr.DanielWienerJanuary2023PlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=simu_Dr.DanielWienerFebruary2024PlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |